Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states

Pharmacopsychiatry

Volumn 32, Issue 4, 1999, Pages 136-141

  Perugi, G ^a   Toni, C ^a   Ruffolo, G ^a   Sartini, S ^a   Simonini, E ^a   Akiskal, H ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CLONAZEPAM; CLOZAPINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; LITHIUM; OLANZAPINE; PAROXETINE; PERPHENAZINE; PIPAMPERONE; PSYCHOTROPIC AGENT; RISPERIDONE; VALPROIC ACID; VENLAFAXINE;

ADULT; AGED; ARTICLE; ATAXIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; IRRITABILITY; MALE; MANIC DEPRESSIVE PSYCHOSIS; MOOD; PRIORITY JOURNAL; RATING SCALE;

EID: 0032827848     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979219     Document Type: Article

References (31)

1. 1 Bennett J, Goldman WT, Suppes T: Gabapentin for treatment of bipolar schizoaffective disorders. J. Clin. Psychopharmacol. 1997; 2: 141-144
2. 2 Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ: Predictors of response to mood stabilizers. J. Clin. Psychopharmacol. 1997; 16 (1): S24-S31
3. 3 Cassano GB, Musetti L, Perugi G, Mignani V, Soriani A, McNair DM, Akiskal HS: Major depression subcategories: their potentiality for clinical research. In: Diagnosis and treatment of depression. Quo Vadis? Sanofi Group Symposium. Montpelier, France 1987: 91-175
4. 4 Cassano GB, Akiskal HS, Musetti L, Perugi G. Soriani A, Mignani V: Psychopathology, temperament and past course In primary major depressions, 2: toward a redefinition of bipolarity with a new semistructured interview for depression. Psychopathology 1989; 22: 278-288
5. 5 Erfurth A, Kammerer C, Grunze H, Normann C, Walden J: An open label trial of gabapentin in the treatment of acute mania. J. Psychiatr. Res. 1998; 32 (5): 261-264
6. 6 Frances A, Docherty JP, Kahn DA: The expert consensus guideline series: treatment of bipolar disorders. J. Clin. Psychiatry 1996; 57 (Suppl. 12a): 5-58
7. 7 Frye MA, Ketter TA, Kimbrell TA, Cora-Locatelli G, Dunn RT, Post RM: Gabapentin and lamotrigine monotherapy in mood disorder. In: Syllabus & Proceedings Summary, 150th Annual Meeting of the APA, San Diego, CA. 1997; 33 (C): 85
8. 8 Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK: Gabapentin treatment of mood disorders: a preliminary study. J. Clin. Psychiatry 1998; 59 (8): 426-429
9. 9 Guy W: ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, Rockville, MD 1976
10. 10 Hamilton M: Development of a rating scale for primary depressive illness. Br. J. Soc Clin. Psychol. 1967; 6: 278-296
11. 11 Knoll J, Stegman K, Suppes T: Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. J. Affect. Disord. 1998; 49 (3); 229-223
12. 12 McElroy SL, Keck PE, Pope HG, Hudson JI, Faedda GL, Swann AC: Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am. J. Psychiatry 1992; 149: 1633-1644
13. 13 McElroy SL, Soutullo CA, Keck PE, Kmetz GF: A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann. Clin. Psychiatry 1997; 9 (2): 99-103
14. 14 McLean MJ: Gabapentin: chemistry, absorption, distribution, and excretion. In: R.H. Levy, R.H. Matson, B.S. Meldrum (eds.). Antiepileptic drugs, 4th ed. Raven Press, New York 1995: 829-841
15. 15 Marcotte DB: Gabapentin: an effective therapy for patients with bipolar affective disorder. 150th Annual Meeting of the APA, San Diego, CA. 1997; No. 261: 138
16. 16 Pande AC, Davidson JRT, Greist JH, Jefferson JW, Weisler R, Sutherland S: A placebo controlled trial study of gabapentin in social phobia. Am. Coll. Neuropsychopharmacol. Poster Session 1997; 1: 141
17. 17 Perugi G, Musetti L, Simonini E, Piagentini F, Cassano GB, Akiskal HS: Gender-mediated clinical features of depressive illness: the importance of temperamental differences, Br. J. Psychiatry 1990; 157: 835-841
18. 18 Perugi G, Akiskal HS, Micheli C, Musetti L, Paiano A, Quilici C, Rossi L, Cassano GB: Clinical subtypes of bipolar mixed states: validating a broader European definition in 143 cases. J. Affect. Disord. 1997; 43: 169-180
19. 19 Pollack MH, Scott EL: Gabapentin and lamotrigine: novel treatments for mood and anxiety disorders. CNS Spectrums 1997; 2 (10): 56-61
20. 20 Pollack MH, Matthews MD, Scott EL: Gabapentin as a potential treatment for anxiety disorders. Am. J. Psychiatry 1998; 155: 992-993
21. 21 Post RM, Denicoff KD, Frye MA, Dunn RT, Leverich GS, Osuch E, Speer A: A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 1998; 38: 152-166
22. 22 Ramsay RE: Gabapentin: toxicity. In: R.H. Levy, R.H. Matson, B.S. Meldrum (eds.). Antiepileptic drugs, 4th ed. Raven Press, New York 1995: 857-860
23. 23 Ryback R, Ryback L: Gabapentin for behavioral dyscontrol. Am. J. Psychiatry 1995; 152: 1399
24. 24 Ryback RS, Brodsky L, Munasifi F: Gabapentin in bipolar disorder. J. Neuropsychiatry Clin. Neurosci. 1997; 9: 301
25. 25 Schaffer CB, Schaffer LC: Gabapentin in the treatment of bipolar disorder. Am. J. Psychiatry 1997; 154 (2): 291-292
26. 26 Short C, Cooke L: Hypomania induced by gabapentin. Br. J. Psychiatry 1995; 166: 679-680
27. 27 Soutullo CA, Casuto LS, Keck PE: Gabapentin in the treatment of adolescent mania: a case report. J. Child Adolesc. Psychopharmacol. 1998; 8 (1): 81-85
28. 28 Stanton SP, Keck PE, McElroy SL: Treatment of acute mania with gabapentin. Am. J. Psychiatry 1997; 154 (2): 289
29. 29 Young LT: Gabapentin in bipolar disorder. American Psychiatric Association Annual Meeting, Toronto, Ontario, Canada 1998; No. NR67: 85
30. 30 Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 1978; 133: 429-435
31. 31 Young LT, Robb J, Patelis-Siotis I, MacDonald C, Joffe RT: Acute treatment of bipolar depression with gabapentin. Biol. Psychiatry 1997; 42: 851-853